Photocure granted patent in Europe and Russia for Visonac in the treatment of acne

01-Dec-2009

Both the European Patent Office and the Patent Office in Russia have issued decisions to grant a patent on Photocure's patent application "PDT Acne". The granted patents will provide protection for the use of the 5-ALA-ester methyl aminolevulinate (MAL- the active ingredient in VisonacTM) and other 5-ALA-esters in the treatment of acne until November 2025.

"We are very pleased with these decisions giving a strong patent protection on Photocure's lead dermatology product", says Kjetil Hestdal, President and CEO of Photocure. "Patent protection of our products is key to succeed in the market".

VisonacTM is a photodynamic therapy that combines the VisonacTM cream with illumination by a red light source to treat acne. Visonac(TM) cream contains MAL. The cream is applied to the acne area to be treated and after a short incubation time, the skin is illuminated with red light. The PDT procedure kills bacteria and appears to have a beneficial effect on sebaceous glands and inflammatory cells.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...